<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2026-3238</article-id><article-id custom-type="edn" pub-id-type="custom">SYIVDS</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-3238</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>Heart failure with preserved ejection fraction in middle-aged women and history of adverse pregnancy outcomes</article-title><trans-title-group xml:lang="ru"><trans-title>Сердечная недостаточность с сохраненной фракцией выброса у женщин среднего возраста и неблагоприятные факторы и исходы беременности в анамнезе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3274-2290</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шперлинг</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shperling</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шперлинг Максим Игоревич  </p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990 </p></bio><bio xml:lang="en"><p>Max I. Shperling </p><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990 </p></bio><email xlink:type="simple">MaxCardio@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-3682-3216</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Косулина</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosulina</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Косулина Василиса Михайловна </p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990 </p></bio><bio xml:lang="en"><p>Vasilisa M. Kosulina </p><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990 </p></bio><email xlink:type="simple">vasilisa.kosulina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-5115-4163</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тимофеев</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Timofeev</surname><given-names>Yu. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тимофеев Юрий Сергеевич  </p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990 </p></bio><bio xml:lang="en"><p>Yuriy S. Timofeev </p><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990 </p></bio><email xlink:type="simple">timofeev_lab@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0430-2754</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Любимова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyubimova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Любимова Нина Васильевна </p><p>Каширское шоссе, д. 23, Москва, 115522 </p></bio><bio xml:lang="en"><p>Nina V. Lyubimova </p><p>Kashirskoe shosse, 23, Moscow, 115522 </p></bio><email xlink:type="simple">biochimia@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8593-1098</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Климанов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Klimanov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Климанов Игорь Александрович </p><p>Каширское шоссе, д. 23, Москва, 115522 </p></bio><bio xml:lang="en"><p>Igor A. Klimanov </p><p>Kashirskoe shosse, 23, Moscow, 115522 </p></bio><email xlink:type="simple">igorklimanov@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5384-3795</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Джиоева</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Dzhioeva </surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Джиоева Ольга Николаевна  </p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990 </p></bio><bio xml:lang="en"><p>Olga N. Dzhioeva </p><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990 </p></bio><email xlink:type="simple">ODzhioeva@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драпкина Оксана Михайловна</p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990 </p></bio><bio xml:lang="en"><p>Oksana M. Drapkina </p><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990 </p></bio><email xlink:type="simple">ODrapkina@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России<country>Россия</country></aff><aff xml:lang="en">National Medical Research Center for Therapy and Preventive Medicine<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Blokhin National Medical Research Center of Oncology<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>11</day><month>04</month><year>2026</year></pub-date><volume>22</volume><issue>1</issue><fpage>4</fpage><lpage>13</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Shperling M.I., Kosulina V.M., Timofeev Y.S., Lyubimova N.V., Klimanov I.A., Dzhioeva  O.N., Drapkina O.M., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Шперлинг М.И., Косулина В.М., Тимофеев Ю.С., Любимова Н.В., Климанов И.А., Джиоева О.Н., Драпкина О.М.</copyright-holder><copyright-holder xml:lang="en">Shperling M.I., Kosulina V.M., Timofeev Y.S., Lyubimova N.V., Klimanov I.A., Dzhioeva  O.N., Drapkina O.M.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/3238">https://www.rpcardio.online/jour/article/view/3238</self-uri><abstract><sec><title>Aim</title><p>Aim. To determine the associations between adverse pregnancy outcomes (APOs) and the presence of heart failure with preserved ejection fraction (HFpEF) in middleaged women.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 102 women aged 45-59 years with a history of at least one completed pregnancy. The examination protocol involved transthoracic echocardiography, with a diastolic stress test when indicated, measurement of NT-proBNP levels, and structured interviews to obtain a history of APOs. Intergroup differences in cardiac structure and function were analyzed, along with associations between APOs and different HFpEF stages.</p></sec><sec><title>Results</title><p>Results. More advanced HFpEF stages in middle-aged women are associated with more pronounced alterations in cardiac morphofunctional parameters and a higher prevalence of hypertension and proteinuria in their pregnancy history. The heart failure risk factor stage (Stage A) showed no statistically significant associations with APOs (p&gt;0.05). Pre-heart failure (Stage B) was associated with hypertension (odds ratio, OR 3.57 (1.43-8.88), p=0.006), proteinuria (OR 4.92 (1.29-18.84), p=0.02), and preterm birth (OR 3.65 (1.20-11.11), p=0.022). Stage 1 HFpEF (Stage C) was linked to hypertension (OR 3.81 (1.08-13.39), p=0.037) and smoking (OR 4.46 (1.09-18.2), p=0.038) during pregnancy. Women with a history of hypertension during pregnancy exhibited higher blood pressure, greater prevalence of hypertension, diabetes mellitus, signs/symptoms of heart failure, worse echocardiographic parameters, and a higher rate of diastolic dysfunction (37.9% vs. 14.9%, p=0.03) in middle age compared to those without hypertensive disorders of pregnancy.</p></sec><sec><title>Conclusion</title><p>Conclusion. A history of hypertension, proteinuria, and smoking during pregnancy is associated with various HFpEF stages in the long term. Middle-aged women with a history of gestational hypertension are characterized by more pronounced alterations in cardiac morphofunctional parameters.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Изучить ассоциации между неблагоприятными факторами и исходами беременности (НФИБ) и наличием сердечной недостаточности с сохраненной фракцией выброса (СНсФВ) у пациенток средней возрастной группы.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследовании приняли участие 102 женщины 45-59 лет, имевшие в анамнезе как минимум одну беременность, завершившуюся родоразрешением. Проводилась трансторакальная эхокардиография (ЭхоКГ), при необходимости с дополнительным диастолическим стресс-тестом. Определялся уровень N-концевого промозгового натрийуретического пептида в крови, а также собирались данные о наличии НФИБ с помощью индивидуального интервьюирования. Анализировались межгрупповые различия показателей функции и структуры сердца, а также связи разных стадий развития СНсФВ с отдельно взятыми НФИБ.</p></sec><sec><title>Результаты</title><p>Результаты. У женщин среднего возраста более тяжелые стадии развития СНсФВ сопровождаются более значимыми нарушениями морфофункциональных параметров сердца и повышенной частотой артериальной гипертензии (АГ) и протеинурии в акушерском анамнезе. Стадия риска развития СН (стадия А) не демонстрировала статистически значимых связей с НФИБ (p&gt;0,05). Для предстадии СН (стадия В) были выявлены ассоциации с АГ — отношение шансов (ОШ) 3,57 (1,43–8,88) (p=0,006), протеинурией — ОШ 4,92 (1,29-18,84) (p=0,02) и случаями преждевременных родов — ОШ 3,65 (1,20-11,11) (p=0,022) в период гестации. 1 стадия СНсФВ (стадия С) ассоциировалась с АГ — ОШ 3,81 (1,08-13,39) (p=0,037) и курением — ОШ 4,46 (1,09–18,2) (p=0,038) во время беременности. У пациенток с гестационной АГ в анамнезе в среднем возрасте регистрируются более высокие уровни артериального давления, большая распространенность гипертонической болезни, сахарного диабета, симптомов СН, нарушенные эхокардиографические показатели и чаще выявляляется диастолическая дисфункция (37,9% против 14,9%, p=0,03) по сравнению с женщинами без указаний на АГ в период беременности.</p></sec><sec><title>Заключение</title><p>Заключение: АГ, курение и протеинурия, зарегистрированные в период беременности, демонстрируют связь с различными этапами континуума СНсФВ в отдаленном периоде. Для женщин среднего возраста с АГ в акушерском анамнезе характерны более выраженные изменения морфофункциональных показателей сердца.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечная недостаточность</kwd><kwd>СНсФВ</kwd><kwd>неблагоприятные исходы беременности</kwd><kwd>осложнения гестации</kwd><kwd>артериальная гипертензия беременных</kwd><kwd>женщины среднего возраста</kwd><kwd>протеинурия</kwd><kwd>курение</kwd><kwd>сердечно-сосудистые осложнения</kwd><kwd>стадия предсердечной недостаточности</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure</kwd><kwd>HFpEF</kwd><kwd>adverse pregnancy outcomes</kwd><kwd>pregnancy complications</kwd><kwd>hypertension during pregnancy</kwd><kwd>middle-aged women</kwd><kwd>proteinuria</kwd><kwd>smoking</kwd><kwd>cardiovascular complications</kwd><kwd>pre-heart failure</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Borlaug BA, Sharma K, Shah SJ, et al. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. J Am Coll Card. 2023;81(18):1810-1834. DOI:10.1016/j.jacc.2023.01.049.</mixed-citation><mixed-citation xml:lang="en">Borlaug BA, Sharma K, Shah SJ, et al. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. J Am Coll Card. 2023;81(18):1810-1834. DOI:10.1016/j.jacc.2023.01.049.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2022;118(17):3272-3287. DOI:10.1093/cvr/cvac013.</mixed-citation><mixed-citation xml:lang="en">Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2022;118(17):3272-3287. DOI:10.1093/cvr/cvac013.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. DOI:10.1161/CIR.0000000000001063.</mixed-citation><mixed-citation xml:lang="en">Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. DOI:10.1161/CIR.0000000000001063.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Omote K, Verbrugge FH, Borlaug BA. Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. Annu Rev Med. 2022;73:321-337. DOI:10.1146/annurev-med-042220-022745.</mixed-citation><mixed-citation xml:lang="en">Omote K, Verbrugge FH, Borlaug BA. Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. Annu Rev Med. 2022;73:321-337. DOI:10.1146/annurev-med-042220-022745.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020;21(4):531-540. DOI:10.31083/j.rcm.2020.04.154.</mixed-citation><mixed-citation xml:lang="en">Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020;21(4):531-540. DOI:10.31083/j.rcm.2020.04.154.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ding N, Shah AM, Blaha MJ, et al. Cigarette Smoking, Cessation, and Risk of Heart Failure With Preserved and Reduced Ejection Fraction. J Am Coll Cardiol. 2022;79(23):2298-2305. DOI:10.1016/j.jacc.2022.03.377.</mixed-citation><mixed-citation xml:lang="en">Ding N, Shah AM, Blaha MJ, et al. Cigarette Smoking, Cessation, and Risk of Heart Failure With Preserved and Reduced Ejection Fraction. J Am Coll Cardiol. 2022;79(23):2298-2305. DOI:10.1016/j.jacc.2022.03.377.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Beale AL, Meyer P, Marwick TH, et al. Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(2):198-205. DOI:10.1161/CIRCULATIONAHA.118.034271.</mixed-citation><mixed-citation xml:lang="en">Beale AL, Meyer P, Marwick TH, et al. Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(2):198-205. DOI:10.1161/CIRCULATIONAHA.118.034271.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hansen AL, Søndergaard MM, Hlatky MA, et al. Adverse Pregnancy Outcomes and Incident Heart Failure in the Women’s Health Initiative. JAMA Netw Open. 2021;4(12):e2138071. DOI:10.1001/jamanetworkopen.2021.38071.</mixed-citation><mixed-citation xml:lang="en">Hansen AL, Søndergaard MM, Hlatky MA, et al. Adverse Pregnancy Outcomes and Incident Heart Failure in the Women’s Health Initiative. JAMA Netw Open. 2021;4(12):e2138071. DOI:10.1001/jamanetworkopen.2021.38071.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Briller JE, Mogos MF, Muchira JM, et al. Pregnancy Associated Heart Failure With Preserved Ejection Fraction: Risk Factors and Maternal Morbidity. J Card Fail. 2021;27(2):143-152. DOI:10.1016/j.cardfail.2020.12.020.</mixed-citation><mixed-citation xml:lang="en">Briller JE, Mogos MF, Muchira JM, et al. Pregnancy Associated Heart Failure With Preserved Ejection Fraction: Risk Factors and Maternal Morbidity. J Card Fail. 2021;27(2):143-152. DOI:10.1016/j.cardfail.2020.12.020.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Garovic VD, White WM, Vaughan L, et al. Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy. Journal of the American College of Cardiology. 2020;75(18):2323-2334. DOI:10.1016/j.jacc.2020.03.028.</mixed-citation><mixed-citation xml:lang="en">Garovic VD, White WM, Vaughan L, et al. Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy. Journal of the American College of Cardiology. 2020;75(18):2323-2334. DOI:10.1016/j.jacc.2020.03.028.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen JB, Schrauben SJ, Zhao L, et al. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail. 2020;8(3):172-184. DOI:10.1016/j.jchf.2019.09.009.</mixed-citation><mixed-citation xml:lang="en">Cohen JB, Schrauben SJ, Zhao L, et al. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail. 2020;8(3):172-184. DOI:10.1016/j.jchf.2019.09.009.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Мацкеплишвили С.Т., Саидова М.А., Мироненко М.Ю., и др. Выполнение стандартной трансторакальной эхокардиографии. Методические рекомендации 2024. Российский кардиологический журнал. 2025;30(2):6271 DOI:10.15829/1560-4071-2025-6271</mixed-citation><mixed-citation xml:lang="en">Matskeplishvili ST, Saidova MA, Mironenko MU, et al. Performing standard transthoracic echocardiography. Methodological recommendations 2024. Russ J Cardiol. 2025;30(2):6271. DOI:10.15829/1560-4071-2025-6271 (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Smiseth OA, Morris DA, Cardim N, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging. 2022;23(2):e34-e61. DOI:10.1093/ehjci/jeab154.</mixed-citation><mixed-citation xml:lang="en">Smiseth OA, Morris DA, Cardim N, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging. 2022;23(2):e34-e61. DOI:10.1093/ehjci/jeab154.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. DOI:10.1016/j.echo.2014.10.003.</mixed-citation><mixed-citation xml:lang="en">Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. DOI:10.1016/j.echo.2014.10.003.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Галявич А.С., Терещенко С.Н., Ускач Т.М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162</mixed-citation><mixed-citation xml:lang="en">Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol. 2024;29(11):6162 (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-3317. DOI:10.1093/eurheartj/ehz641.</mixed-citation><mixed-citation xml:lang="en">Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-3317. DOI:10.1093/eurheartj/ehz641.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. DOI:10.1093/eurheartj/ehab368.</mixed-citation><mixed-citation xml:lang="en">McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. DOI:10.1093/eurheartj/ehab368.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, et al. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(3):413-421. DOI:10.1002/ejhf.1614.</mixed-citation><mixed-citation xml:lang="en">Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, et al. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(3):413-421. DOI:10.1002/ejhf.1614.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Verbrugge FH, Omote K, Reddy YNV, et al. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J. 2022;43(20):1941-1951. DOI:10.1093/eurheartj/ehab911.</mixed-citation><mixed-citation xml:lang="en">Verbrugge FH, Omote K, Reddy YNV, et al. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J. 2022;43(20):1941-1951. DOI:10.1093/eurheartj/ehab911.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ying W, Catov JM, Ouyang P. Hypertensive Disorders of Pregnancy and Future Maternal Cardiovascular Risk. Journal of the American Heart Association. 2018;7(17):e009382. DOI:10.1161/JAHA.118.009382.</mixed-citation><mixed-citation xml:lang="en">Ying W, Catov JM, Ouyang P. Hypertensive Disorders of Pregnancy and Future Maternal Cardiovascular Risk. Journal of the American Heart Association. 2018;7(17):e009382. DOI:10.1161/JAHA.118.009382.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Чулков ВС, Сюндюкова ЕГ, Чулков ВС, и др. Гипертензивные нарушения во время беременности и риск сердечно-сосудистых заболеваний. Профилактическая Медицина. 2021;24(12):97-104. DOI:10.17116/profmed20212412197</mixed-citation><mixed-citation xml:lang="en">Chulkov VS, Syundyukova EG, Chulkov VS, et al. Hypertensive disorders during pregnancy and the risk of cardiovascular diseases. Preventive Medicine. 2021;24(12):97-104. DOI:10.17116/profmed20212412197 (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Umar S, Banerjee S, Datta S, et al. Perinatal Nicotine Exposure in Rats Leads to HFpEF, Pulmonary Hypertension, and Right Ventricular Hypertrophy Which Are Attenuated by a Potent PPARγ Agonist Rosiglitzaone. Am J Respir Crit Care Med 2024;209:A6807. DOI:10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A6807.</mixed-citation><mixed-citation xml:lang="en">Umar S, Banerjee S, Datta S, et al. Perinatal Nicotine Exposure in Rats Leads to HFpEF, Pulmonary Hypertension, and Right Ventricular Hypertrophy Which Are Attenuated by a Potent PPARγ Agonist Rosiglitzaone. Am J Respir Crit Care Med 2024;209:A6807. DOI:10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A6807.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
